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Background: In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung
adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and
prognostic and predictive utility of cfDNA positivity (cfDNAþ ).
Methods: Paired tumour and blood samples were prospectively collected from randomised patients. Mutations were detected
using cfDNA from serum (LL3) or plasma (LL6) by a validated allele-specific quantitative real-time PCR kit.
Results: EGFR mutation detection rates in cfDNA were 28.6% (serum) and 60.5% (plasma). Mutation detection in blood was
associated with advanced disease characteristics, including higher performance score, number of metastatic sites and bone/liver
metastases, and poorer prognosis. In patients with common EGFR mutations, afatinib improved progression-free survival vs
chemotherapy in cfDNAþ (LL3: HR, 0.35; P¼ 0.0009; LL6: HR, 0.25; Po0.0001) and cfDNA (LL3: HR, 0.46; Po0.0001; LL6: HR,
0.12; Po0.0001) cohorts. A trend towards overall survival benefit with afatinib was observed in cfDNAþ patients.
Conclusions: Plasma cfDNA is a promising alternative to biopsy for EGFR testing. Detectable mutation in blood was associated
with more advanced disease and poorer prognosis. Afatinib improved outcomes in EGFR mutation-positive patients regardless of
blood mutation status.
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Traditionally, treatment of non-small cell lung cancer (NSCLC)
has consisted of platinum-based chemotherapy. However, over the
past decade, the discovery of frequent molecular alterations in
NSCLC, particularly epidermal growth factor receptor (EGFR)
mutations, has led to a new treatment paradigm that includes
targeted agents (Novello et al, 2016). The reversible EGFR tyrosine
kinase inhibitors (TKIs) erlotinib and gefitinib, as well as the
irreversible ErbB family blocker, afatinib, are approved for the
treatment of advanced EGFR mutation-positive NSCLC. In this era
of targeted therapies, identification of patients (e.g., via EGFR
mutation detection) who may derive benefit from these agents is a
key factor for successful treatment (Olsen and Jorgensen, 2014).
In clinical practice, EGFRmutations are routinely detected using
DNA extracted from primary or metastatic tumour tissue obtained
during tumour biopsy or resection, which is typically formalin
fixed and paraffin embedded (FFPE) (Ellison et al, 2013; Jung,
2013). However, efficient and robust mutation testing using these
tissue samples can be challenging owing to small biopsy size or lack
of sufficient tumour cells, inherent issues associated with FFPE
archival tissue (e.g., poor DNA quality and tissue necrosis), and
reluctance or inability of patients to undergo invasive biopsy
(Ellison et al, 2013; Jung, 2013; Weber et al, 2014). As such, the
development of simpler, minimally invasive assays to detect gene
mutations may provide an attractive alternative to tumour biopsy
for the identification of patients eligible for targeted treatments.
An emerging methodology to this end is the detection of mutations
in circulating cell-free DNA (cfDNA) isolated from blood (i.e., liquid
biopsy). Clinical studies in patients with NSCLC have explored the
feasibility of EGFRmutation detection using cfDNA from serum and/
or plasma samples, as well as the prognostic value and potential utility
of EGFRmutation positivity by cfDNA to predict clinical outcomes to
EGFR-targeted therapies (Kimura et al, 2006, 2007; Bai et al, 2009; He
et al, 2009; Brevet et al, 2011; Lee et al, 2011; Goto et al, 2012; Mok
et al, 2013; Li et al, 2014; Douillard et al, 2014a,b; Mok et al, 2015).
These studies suggest that detection of EGFR mutation in the blood is
feasible and may be useful in the absence of available tumour biopsy.
However, there is variability in the detection rates of EGFR mutation
in the blood compared with the standard methodology using tumour
tissue, and the correlation of blood-derived EGFR mutation positivity
with specific patient characteristics or clinical outcomes remains
uncertain.
This article describes the findings of two large, randomised Phase
III trials (LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)), which
compared the ErbB family blocker afatinib with standard platinum-
doublet chemotherapy (cisplatinþ pemetrexed in LL3; cisplatinþ
gemcitabine in LL6) in treatment-naive patients with advanced
NSCLC harbouring EGFR mutations in their tumours (Sequist et al,
2013; Wu et al, 2014; Yang et al, 2015). Improvements in clinical
outcomes with afatinib vs chemotherapy in both LL3 and LL6,
particularly in patients with tumours harbouring common EGFR
mutations (Del19/L858R), have been previously reported (Sequist
et al, 2013; Wu et al, 2014; Yang et al, 2015). Both trials prospectively
collected paired tumour and blood samples from patients for analysis
of EGFR mutations. The current analysis evaluates the technical
feasibility of detecting EGFR mutations in cfDNA from either serum
(LL3) or plasma (LL6) and explores the association of clinical
characteristics and outcomes with cfDNA-positive (cfDNAþ ) or
-negative (cfDNA ) status in EGFR mutation-positive patients.
MATERIALS AND METHODS
Study design and patients. Details of the LL3 and LL6 study
designs and patient eligibility criteria have been previously
published (Sequist et al, 2013; Wu et al, 2014). In brief, eligible
patients in LL3 (n¼ 345; recruited globally) and LL6 (n¼ 364;
recruited in China, South Korea, and Thailand) had pathologically
confirmed and previously untreated stage IIIB/IV lung adenocar-
cinoma, an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1 (Eisenhauer et al, 2009), and adequate organ function.
Tumours were confirmed as EGFR mutation positive at screening
based on central laboratory analysis of biopsy tissue using a
validated test kit (Therascreen EGFR 29; Qiagen, Manchester, UK),
as described in detail below.
In each study, patients were randomised (2 : 1) to receive oral
afatinib (40mg day 1) or up to six cycles of intravenous
pemetrexed (500mgm 2) plus cisplatin (75mgm 2) once every
21 days in LL3 or gemcitabine (1000mgm 2; days 1 and 8) plus
cisplatin (75mgm 2; day 1) every 21 days in LL6 (Sequist et al,
2013; Wu et al, 2014). Stratification parameters included EGFR
mutation type (Del19/L858R/other) and race (Asian/non-Asian;
LL3 only). Patients were treated until disease progression, death,
unacceptable adverse events or withdrawal of consent for any
reason.
The primary end point of each study was progression-free
survival (PFS; by independent blinded review) (Sequist et al, 2013;
Wu et al, 2014). Key secondary end points for both studies
included objective response (complete response (CR) or partial
response (PR)), disease control (CR, PR or stable disease), and
overall survival (OS). Other secondary end points included patient-
reported outcomes of disease symptoms and health-related quality
of life and safety, which were previously published (Sequist et al,
2013; Wu et al, 2014).
Study conduct. Each study was conducted in accordance with the
Declaration of Helsinki, International Conference on Harmonisa-
tion good clinical practice, local laws, and applicable regulatory
requirements and was approved by the institutional review board
or independent ethics committee of each centre. An independent
Data Monitoring Committee monitored conduct. All patients
provided written, informed consent for participation in the studies
and provision of tumour and blood samples. Trial registration IDs
are: ClinicalTrials.gov NCT00949650 (LL3) and NCT01121393
(LL6).
Blood/tumour sample collection and EGFR mutation detection.
Tumour tissue from each patient was obtained at an initial
diagnostic procedure for NSCLC and was paraffin embedded.
Tumour samples for EGFR mutation detection consisted of at least
five 10 mm unstained sections mounted on a non-charged
microscopic slide and containing at least 20% tumour tissue. In
addition to the tumour tissue sample, a mandatory 9-ml blood
sample was collected from each patient at the start of treatment
(day 1, course 1) in both trials; however, different DNA extraction
methodologies were used (see below for further details). The
selection of the DNA extraction kit was based on the recommen-
dation from the manufacturer at the time of each study conduct.
In both tumour tissue and paired serum/plasma samples,
genotyping of EGFR mutations was conducted at a central
laboratory using a validated allele-specific quantitative real-time
PCR kit (Therascreen EGFR 29; Qiagen) designed to detect 29
EGFR mutations (19 deletions in exon 19 (collectively termed
Del19), L858R, three insertions in exon 20 (collectively termed
Ins20), L861Q, G719S, G719A, G719C (or G719X), T790M, and
S768I) against a background of wild-type genomic DNA. Although
a formal assessment of the amount of serum/plasma used for each
sample was not conducted, it is important to note that the
Therascreen EGFR 29 assay includes DNA-loading controls, which
indicate when a DNA sample is too dilute or is non-amplifiable,
and provides a means of performing quality control of the DNA
during the assay.
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Extraction of DNA from serum. Following phlebotomy (9ml of
venous blood collected over ethylenediaminetetraacetic acid
(EDTA)), serum was prepared and frozen prior to shipment to
the central laboratory. DNA preparation from frozen serum
samples (3ml) was performed using the QIAamp DNA Blood Mini
Kit (Qiagen) according to the manufacturer’s instructions.
Extraction of DNA from plasma. Following phlebotomy (9ml of
venous blood collected over EDTA), plasma was prepared and
frozen prior to shipment to the central laboratory. The EDTA
plasma sample was thawed at room temperature and then trans-
ferred to a 15-ml tube and centrifuged for 10min at 16 000 g in a
fixed-angle rotor at þ 4 1C. Proteinase K solution (400 ml) was
added to a 50-ml tube. The clarified plasma supernatant was
carefully separated from the sediment layer, and a maximum of
4ml was added to the Proteinase K solution. The sample volume
was then adjusted to 4ml as required using phosphate-buffered
saline. Buffer ACL (3.2ml, containing carrier RNA) was added to
the 50-ml tube and the solution was incubated at 60 1C for 30min.
The Proteinase K-digested sample was then further processed as
per the QIAamp Circulating Nucleic Acid Kit manufacturer’s
instructions (Qiagen), and the final DNA samples were eluted in
100ml of buffer AVE.
Tumour assessments. Tumour assessments were performed by
computed tomography or magnetic resonance imaging every 6
weeks for the first 48 weeks and then every 12 weeks thereafter
until disease progression or start of new anticancer therapy
(Sequist et al, 2013; Wu et al, 2014). Scans were reviewed by an
independent central imaging group consisting of both radiologists
and oncologists who were blinded to treatment assignments.
Number of metastatic sites was determined by the count of unique
sites of metastases across all organs with metastases. The sum of
the longest diameters of lesions is the sum of the baseline target
lesions identified by an independent review according to the
procedures defined in RECIST version 1.1 (Eisenhauer et al, 2009).
Statistical analyses. To formally define the performance of the
EGFR Therascreen 29 assay, test results from a mixture of EGFR
mutation-positive and -negative samples would be required to
calculate the sensitivity, specificity, negative predictive value
(NPV), and positive predictive value (PPV) of the assay. Per
eligibility criteria in LL3 and LL6, only patients with EGFR
mutation-positive tumours were included (i.e., all patients had
tumour tissue that was positive for one or more EGFR mutation
type). As such, calculations for sensitivity, specificity, PPV, and
NPV in this analysis make use of test results for all seven mutation
types within each individual patient.
For each study, logistic regression models were used to test for
any association between baseline demographic and disease
characteristics and the EGFR mutation test result from blood
(cfDNAþ or cfDNA ). Separate efficacy analyses were per-
formed on patients who were cfDNAþ or cfDNA in each
study. Comparisons of PFS and OS between treatment arms were
made via a log-rank test. Cox proportional-hazard models were
used to derive hazard ratios (HRs) and 95% confidence intervals
(CIs) comparing the two treatment arms. Kaplan–Meier estimates
were used to construct survival curves and calculate median PFS
and OS. Logistic regression models were used to compare the rates
of objective response and disease control between treatment
groups. Additional Cox proportional-hazard models were used to
assess whether the blood test result (cfDNAþ or cfDNA ) was
prognostic for PFS or OS after adjusting for any effects of
treatment. Further Cox proportional-hazard models were used,
including the treatment-by-blood test result interaction term, in
order to evaluate any evidence of heterogeneity. Efficacy analyses
were restricted to those patients with an EGFR mutation blood test
result whose tumour harboured a common EGFR mutation
(Del19/L858R). Analyses were performed on all such patients
and also for patients split by the type of mutation (Del19 or L858R)
in the tumour. Efficacy data presented here are from the time point
of the main OS analysis, when it was estimated that OS would be
sufficiently mature (Yang et al, 2015). All analyses were post hoc
and exploratory in nature.
RESULTS
EGFR mutations in blood cfDNA and matched tumour tissue.
In LL3 and LL6, 287 (serum) and 334 (plasma) blood samples were
analysed for the presence of EGFR mutations (Figure 1). The
detection rates of EGFR mutation using cfDNA from blood
samples compared with paired tumour samples were 28.6% (82 out
of 287) in LL3 and 60.5% (202 out of 334) in LL6. Detection rates
for individual EGFR mutations, including the common mutations
Del19 and L858R, as well as various uncommon mutations, are
shown in Table 1.
Characteristics of patients with or without detectable EGFR
mutation in the blood. Descriptive summaries supported by
statistical tests of association showed that, in both trials, patients
who were cfDNAþ for EGFR exhibited characteristics associated
with more advanced disease compared with cfDNA patients.
cfDNAþ patients more frequently had a higher ECOG perfor-
mance status (LL3: P¼ 0.0029; LL6: P¼ 0.0022), greater tumour
burden (measured as the sum of the longest diameter of
target lesions; approaching significance in LL3: P¼ 0.061;
LL6: P¼ 0.0001), more metastatic sites (LL3: P¼ 0.0003; LL6:
Po0.0001), and metastases to the bone (LL3 and LL6: Po0.0001)
and liver (LL3: Po0.0001; LL6: P¼ 0.0003; Table 2). In terms of
laboratory parameters, the cfDNAþ group also exhibited a
general trend in higher laboratory values for alkaline phosphatase
(ALP), lactate dehydrogenase (LDH), and white blood cell count
(approaching significance for LL6), which are associated with
metastatic spread to the bone and liver (2015). In addition, there
was evidence in LL6 that female patients and those with a poorly/
undifferentiated tumour grade were more likely to be cfDNAþ
than cfDNA . No notable differences were observed based on
age, race, smoking status, disease stage, pleural metastases, brain
metastases, or original EGFR mutation type in the tumour in either
study.
Efficacy analysis by cfDNA EGFR mutation detection status.
Efficacy analyses were performed in NSCLC patients whose
tumours harboured common EGFR mutations (Del19 or L885R)
confirmed by tissue biopsy. Within this group of patients,
comparisons between treatment arms (afatinib vs chemotherapy)
were performed in those who were cfDNAþ or cfDNA for any
EGFR mutation based on their blood test result.
Survival outcomes. Afatinib significantly improved PFS vs
chemotherapy in patients with common EGFR mutations in both
the cfDNAþ (LL3: 8.3 vs 3.3 months; P¼ 0.0009; LL6: 9.7 vs 4.6
months; Po0.0001) and the cfDNA group (LL3: 13.7 vs 6.9
months; Po0.0001; LL6: 16.6 vs 5.8 months; Po0.0001; Figure 2).
The PFS benefit of afatinib over chemotherapy was more
pronounced in patients with Del19 vs L858R mutation-positive
tumours (Table 3).
A trend towards improvement in OS with afatinib vs
chemotherapy was observed in patients who were cfDNAþ
(LL3: 22.1 vs 14.7 months; LL6: 20.0 vs 17.8 months) or
cfDNA (LL3: 33.6 vs 28.6 months; LL6: 35.6 vs 27.0 months;
Figure 3). In Del19 patients, a statistically significant improve-
ment in OS with afatinib vs chemotherapy was observed in
cfDNAþ patients in LL3 (29.4 vs 14.3 months; P¼ 0.0372) and
in cfDNA patients in both trials (LL3: 33.3 vs 28.2 months;
www.bjcancer.com |DOI:10.1038/bjc.2016.420 177
EGFR mutation analysis in cfDNA of NSCLC patients BRITISH JOURNAL OF CANCER
P¼ 0.0247; LL6: 39.4 vs 21.1 months; P¼ 0.0063; Table 3). OS
was numerically improved in Del19 patients with a detectable
EGFR mutation in plasma in LL6 (23.6 vs 14.6 months). No
difference in OS with afatinib vs chemotherapy was observed in
the L858R group for those with or without a detectable EGFR
mutation in the blood (Table 3).
cfDNAþ patients had generally shorter PFS and OS in both
treatment arms than cfDNA patients (Supplementary Figures S1
Table 1. Detection of individual EGFR mutations between paired blood-derived cfDNA samplesa and tumour tissue samplesb
Tumour tissue/cfDNA
Mutation type þ /þ þ /  /  /þ cfDNA no result Sensitivity (%) Specificity (%) PPV (%) NPV (%)
LUX-Lung 3
Del19c 49 98 131 4 5 33.3 97.0 92.5 57.2
L858Rc 26 93 160 2 6 21.8 98.8 92.9 63.2
Exon20c 0 5 272 1 9 0.0 99.6 0.0 98.2
G719Xc 0 5 272 0 10 0.0 100.0 – 98.2
L861Qc 1 5 270 1 10 16.7 99.6 50.0 98.2
S768Ic 1 3 273 0 10 25.0 100.0 100.0 98.9
T790Mc 3 7 264 1 12 30.0 99.6 75.0 97.4
Overall concordanced 82 205
%d 28.60
LUX-Lung 6
Del19c 112 63 149 4 6 64.0 97.4 96.6 70.3
L858Rc 70 57 200 1 6 55.1 99.5 98.6 77.8
Exon20c 5 2 321 0 6 71.4 100.0 100.0 99.4
G719Xc 5 13 310 0 6 27.8 100.0 100.0 96.0
L861Qc 8 3 317 0 6 72.7 100.0 100.0 99.1
S768Ic 3 4 321 0 6 42.9 100.0 100.0 98.8
T790Mc 0 1 326 1 6 0 99.7 0.0 99.7
Overall concordanced 202 132
%d 60.50
Abbreviations: cfDNA¼ cell-free DNA; EGFR¼epidermal growth factor receptor; NPV¼negative predictive value; PPV¼positive predictive value.
aSerum in LUX-Lung 3 and plasma in LUX-Lung 6.
bNo patients included in this analysis were EGFR mutation negative; all patients had tumour tissue that was positive for one or more mutation type. The calculations for sensitivity, specificity,
PPV and NPV make use of test results for all seven mutation types within each individual patient.
cAllele-level concordance.
dOverall (patient level) concordance of cfDNA mutation status compared with tumour tissue.
LUX-Lung 6LUX-Lung 3
345 EGFR mutation-positivea
patients randomised
258 with common EGFR 
mutations (Del19/L858R)
258 included in efficacy analyses 298 included in efficacy analyses
171 received afatinib
50 cfDNA+
121 cfDNA–
87 received chemotherapy
25 cfDNA+
62 cfDNA–
207 received afatinib
135 cfDNA+
72 cfDNA–
91 received chemotherapy
49 cfDNA+
42 cfDNA–
298 with common EGFR 
mutations (Del19/L858R)
364 EGFR mutation-positivea
patients randomised
58 did not have
blood samples
287 included in cfDNA analyses
of baseline characteristics
334 included in cfDNA analyses
of baseline characteristics
30 did not have
blood samples
Figure 1. Patient disposition in LUX-Lung 3 and LUX-Lung 6. aPatients who were EGFR mutation positive based on tissue biopsy at screening.
Abbreviations: cfDNA=cell-free DNA; EGFR=epidermal growth factor receptor.
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Table 2. Baseline and disease characteristics according to the presence of EGFR mutation by cfDNA analysis
LUX-Lung 3 LUX-Lung 6
Characteristics
Serum cfDNAþ
(n¼82)
Serum
cfDNA
(n¼205)
Association OR
(95% CI); P valuea
Plasma
cfDNAþ
(n¼202)
Plasma
cfDNA
(n¼132)
Association OR
(95% CI); P valuea
Gender, n (%)
Male 27 (32.9) 72 (35.1)
1.10 (0.64–1.90); 0.7238
63 (31.2) 57 (43.2)
1.68 (1.06–2.64); 0.0260Female 55 (67.1) 133 (64.9) 139 (68.8) 75 (56.8)
Age, years
Median (range) 61 (38–83) 61 (28–84) 0.94 (0.73–1.22); 0.6487 58 (29–77) 58 (27–78) 1.00 (0.82–1.22); 0.9683
Race, n (%)
Asian 58 (70.7) 149 (72.7)
1.10 (0.63–1.94); 0.7391
202 (100.0) 132 (100.0)
–Non-Asian 24 (29.3) 56 (27.3) 0 0
ECOG PS, n (%)
0 17 (20.7) 81 (39.5)
2.50 (1.37–4.56); 0.0029
36 (17.8) 43 (32.6)
2.23 (1.34–3.72); 0.00221 65 (79.3) 124 (60.5)b 166 (82.2) 89 (67.4)
Smoking status, n (%)
Current 2 (2.4) 4 (2.0) 16 (7.9) 10 (7.6)
Former 23 (28.0) 62 (30.2) 1.08 (0.62–1.88); 0.7789c 26 (12.9) 28 (21.2) 1.54 (0.93–2.56); 0.0953c
Never 57 (69.5) 139 (67.8) 160 (79.2) 94 (71.2)
Adenocarcinoma stage, n (%)
IIIB with pleural
effusion
7 (8.5) 24 (11.7)
1.42 (0.59–3.44); 0.4364
7 (3.5) 10 (7.6)
2.28 (0.85–6.16); 0.1029
IV 75 (91.5) 181 (88.3) 195 (96.5) 122 (92.4)
Differentiation grade, n (%)
Well differentiated 3 (3.7) 27 (13.2)
1.23 (0.67–2.26)d; 1.77
(0.87–3.60)e; 0.2825
10 (5.0) 15 (11.4)
1.56 (0.92–2.65)d; 2.23
(1.27–5.03)e; 0.0295
Moderately
differentiated
19 (23.2) 42 (20.5) 30 (14.9) 25 (18.9)
Poorly differentiated 16 (19.5) 28 (13.7) 46 (22.8) 17 (12.9)
Undifferentiated 6 (7.3) 11 (5.4) 2 (1.0) 2 (1.5)
Not specified 38 (46.3) 97 (47.3) 114 (56.4) 73 (55.3)
Number of metastatic sites, n (%)
0 0 (0.0) 6 (2.9)
1.81 (0.91–4.07)f;
3.94 (1.94–7.98)g; 0.0003
1 (0.5) 3 (2.3)
2.06 (1.22–3.48)f; 4.20
(2.32–7.61)g; o0.0001
1 12 (14.6) 64 (31.2) 50 (24.8) 61 (46.2)
2 18 (22.0) 58 (28.3) 74 (36.6) 45 (34.1)
X3 52 (63.4) 77 (37.6) 77 (38.1) 23 (17.4)
Location of metastatic sites, n (%)
Pleural effusion 43 (52.4) 82 (40.0) 1.65 (0.99–2.77); 0.0558 63 (31.2) 42 (31.8) 0.97 (0.61–1.56); 0.9034
Bone 54 (65.9) 76 (37.1) 3.27 (1.91–5.60); o0.0001 119 (58.9) 28 (21.2) 5.33 (3.22–9.80);o0.0001
Brain 13 (15.9) 27 (13.2) 1.24 (0.61–2.55); 0.5538 24 (11.9) 22 (16.7) 0.67 (0.36–1.26); 0.2166
Liver 25 (30.5) 18 (8.8) 4.56 (2.32–8.95); o0.0001 37 (18.3) 4 (3.0) 7.18 (2.49–20.65); 0.0003
Other 60 (73.2) 142 (69.3) – 164 (81.2) 101 (76.5) –
Median (range) SLD
target lesions, mm
60.5 (14.1–168.5) 45.6 (10.6–167.0) 1.14 (0.99–1.31); 0.0613 56.8 (16.1–175.8) 46.2 (12.0–162.6) 1.35 (1.16–1.58); 0.0001
Tissue EGFR mutation type, n (%)
Common mutations 75 (91.5) 183 (89.3)
0.59 (0.34–1.02)h;
0.62 (0.25–1.56)i; 0.1427
184 (91.1) 114 (86.4)
0.73 (0.46–1.17)h; 0.54
(0.26–1.12)i; 0.1732
Del19 49 (59.8) 96 (46.8) 111 (55.0) 60 (45.5)
L858R 26 (31.7) 87 (42.4) 73 (36.1) 54 (40.9)
Uncommon mutationsj 7 (8.5) 22 (10.7) 18 (8.9) 18 (13.6)
Laboratory parameters, median (range)
WBC count, 109 l1 7.8 (3.2–29.9) 7.0 (2.4–24.4) 1.09 (1.02–1.17); 0.0132 7.4 (2.9–18.6) 6.8 (3.5–24.1) 1.08 (1.00–1.17); 0.0599
LDH, U l 1 287 (125–1706) 245 (93–1160) 1.06 (1.02–1.11); 0.0023 224 (89–1773) 170 (54–431) 1.16 (1.06–1.26);o0.0001
ALP, U l1 124 (40–973) 125 (36–513) 1.10 (1.04–1.17); 0.0025 98 (31–2463) 83 (39–379) 1.49 (1.28–1.74); 0.0006
Abbreviations: ALP¼ alkaline phosphatase; cfDNA¼ cell-free DNA; CI¼ confidence interval; ECOG PS¼Eastern Cooperative Oncology Group performance status; EGFR¼ epidermal growth
factor receptor; LDH¼ lactate dehydrogenase; OR¼odds ratio; SLD¼ sum of longest diameter; WBC¼white blood cell.
aTwo-sided Wald chi-square test from univariate logistic regression analysis.
bIncludes one patient with an ECOG PS of 2.
cNever vs former/current smoker.
dNot specified vs well/moderately differentiated.
eWell/moderately differentiated vs poorly/undifferentiated.
f0/1 vs 2 metastatic sites.
g0/1 vs X3 metastatic sites.
hDel19 vs L858R mutations.
iDel19 vs other mutations.
jIncluding T790M, Ins20, G719X, S768I, and L861Q, alone or as complex mutations in two or more exons.
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and S2). Additional analyses confirmed the prognostic effect of a
detectable EGFR mutation in the blood on PFS and OS; after
adjusting for any effects of treatment, a consistent, statistically
significant effect was observed (Table 3). There was no evidence to
suggest that the treatment effect (afatinib vs chemotherapy) was
different for cfDNAþ or cfDNA patients, as observed by the
non-significant interaction term P values (Table 3).
Tumour response. In both cfDNAþ and cfDNA patients,
higher objective response rates (ORRs) based on independent
review were observed in those treated with afatinib vs chemother-
apy (cfDNAþ ; LL3: 62.0% vs 20.0%; LL6: 69.6% vs 30.6%;
cfDNA ; LL3: 62.8% vs 24.2%; LL6: 69.4% vs 19.0%). Higher
ORRs with afatinib vs chemotherapy in cfDNAþ patients (LL3:
78.0% vs 40.0%; LL6: 76.3% vs 34.7%) and cfDNA patients (LL3:
76.9% vs 45.2%; LL6: 75.0% vs 33.3%) were also observed based on
investigator assessment of tumour response.
DISCUSSION
The development of minimally invasive assays to detect gene
mutations may provide a promising alternative to tumour biopsy,
in the absence of available tissue samples, for identifying patients
who would benefit from genotype-directed therapy such as EGFR-
targeted agents. In the current analysis of NSCLC patients enrolled
in the Phase III LL3 and LL6 trials, the EGFR mutation detection
rates between paired tumour and blood samples suggest that the
isolation of cfDNA from plasma using the QIAamp Circulating
Nucleic Acid Kit (Qiagen) could be a potential alternative to
tumour tissue for EGFR mutation testing in the absence of
available tumour samples. Whether the difference in EGFR
mutation detection rates between LL3 (28.6%) and LL6 (60.5%)
in this analysis was attributable to the different DNA extraction
kits used, the difference in DNA source (serum or plasma), or both
is currently unclear. However, previous studies suggest that plasma
may be a more reliable source than serum for tumour DNA owing
to higher background levels of non-tumour wild-type DNA found
in serum (Steinman, 1975; Board et al, 2008). In a recent analysis of
BRAF mutation testing using amplification refractory mutation
system (ARMS) methodology on cfDNA isolated from either
serum or plasma collected from advanced melanoma patients, a
greater amount of total cfDNA was isolated from serum vs plasma
(using the QIAamp Circulating Nucleic Acid Kit (Qiagen) for each
blood sample type); however, the proportion of tumour-derived
mutant cfDNA was significantly greater in plasma than in serum
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Figure 2. Kaplan–Meier curves of PFS. Kaplan–Meier curves of PFS according to the presence of an EGFR mutation by cfDNA analysisa in
patients with common EGFRmutations (Del19 or L858R; based on tumour biopsy) in (A) LUX-Lung 3 and (B) LUX-Lung 6. aPatients who were EGFR
Del19 or L858R mutation positive based on tissue biopsy were grouped according to whether any EGFRmutation was detected by cfDNA analysis
(cfDNAþ or cfDNA ). Abbreviations: cfDNA=cell-free DNA; cis = cisplatin; EGFR=epidermal growth factor receptor; gem=gemcitabine;
pem=pemetrexed; PFS=progression-free survival.
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Table 3. PFS and OS according to the presence of an EGFR mutation by cfDNA analysisa in patients with common EGFR
mutations (Del19 or L858R; based on tumour biopsy)
cfDNAþ cfDNA
LUX-Lung 3 Afatinib
Cisplatinþ
pemetrexed Afatinib
Cisplatinþ
pemetrexed
Effect of cfDNA
result; P value
Interaction between
treatment and blood test
results; P value
Tissue: common EGFR mutation (Del19 or L858R)
Patients, n 50 25 121 62
Median PFS, months 8.3 3.3 13.7 6.9
Afatinib vs CT,
HR (95% CI); P value
0.35 (0.18–0.67) 0.0009 0.46 (0.31–0.68) o0.0001 0.0037 0.1242
Median OS, months 22.1 14.7 33.6 28.6
Afatinib vs CT,
HR (95% CI) P value
0.64 (0.37–1.11) 0.1062 0.75 (0.50–1.12) 0.1578 0.0003 0.5353
Tissue: Del19
Patients, n 30 19 67 29
Median PFS, months 8.2 3.3 16.4 5.8
Afatinib vs CT,
HR (95% CI) P value
0.30 (0.13–0.67) 0.0017 0.17 (0.09–0.33) o0.0001 0.0382 0.9608
Median OS, months 29.4 14.3 33.3 28.2
Afatinib vs CT,
HR (95% CI) P value
0.50 (0.26–0.97) 0.0372 0.54 (0.32–0.93) 0.0247 0.0355 0.7512
Tissue: L858R
Patients, n 20 6 54 33
Median PFS, months 7.6 2.8 13.6 7.4
Afatinib vs CT,
HR (95% CI) P value
0.40 (0.11–1.50) 0.1593 0.78 (0.46–1.35) 0.3698 0.2097 0.1376
Median OS, months 16.5 14.8 33.9 29.5
Afatinib vs CT,
HR (95% CI) P value
1.12 (0.37–3.40) 0.8422 1.08 (0.59–1.97) 0.8071 0.0086 0.9247
LUX-Lung 6 Afatinib
Cisplatinþ
gemcitabine Afatinib
Cisplatinþ
gemcitabine
Effect of cfDNA
result; P value
Interaction between
treatment and blood test
results; P value
Tissue: common EGFR mutation (Del19 or L858R)
Patients, n 135 49 72 42
Median PFS, months 9.7 4.6 16.6 5.8
Afatinib vs CT,
HR (95% CI) P value
0.25 (0.16–0.39) o0.0001 0.12 (0.06–0.24) o0.0001 o0.0001 0.4057
Median OS, months 20 17.8 35.6 27
Afatinib vs CT,
HR (95% CI) P value
0.78 (0.54–1.13) 0.1841 0.59 (0.36–0.98) 0.0383 o0.0001 0.4405
Tissue: Del19
Patients, n 80 31 41 19
Median PFS, months 11 4.5 16.6 6.9
Afatinib vs CT,
HR (95% CI) P value
0.19 (0.10–0.34) o0.0001 0.10 (0.03–0.28) o0.0001 0.0135 0.7958
Median OS, months 23.6 14.6 39.4 21.1
Afatinib vs CT,
HR (95% CI) P value
0.67 (0.41–1.09) 0.106 0.37 (0.18–0.78) 0.0063 0.0008 0.2101
Tissue: L858R
Patients, n 55 18 31 23
Median PFS, months 8.1 4.6 16.5 5.6
Afatinib vs CT,
HR (95% CI) P value
0.37 (0.18–0.74) 0.0032 0.17 (0.07–0.44) o0.0001 0.0022 0.2846
Median OS, months 17 17.9 27.7 28.2
Afatinib vs CT,
HR (95% CI) P value
0.96 (0.54–1.69) 0.8781 1.10 (0.55–2.21) 0.779 o0.0001 0.7792
Abbreviations: cfDNA¼ cell-free DNA; CI¼ confidence interval; CT¼ chemotherapy; EGFR¼ epidermal growth factor receptor; HR¼ hazard ratio; OS¼overall survival; PFS¼progression-free survival.
aPatients who were EGFR Del19 or L858R mutation positive based on tissue biopsy were grouped according to whether any EGFR mutation was detected by cfDNA analysis (cfDNAþ or cfDNA ).
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(approximately 2 higher) (Aung et al, 2014). Although total
cfDNA isolated from serum vs plasma was not investigated in the
current analysis, it is possible that the higher EGFR mutation
detection rate observed in plasma vs serum may reflect a higher
proportion of tumour-derived mutant cfDNA present in plasma.
In previous analyses, the detection rates for EGFR mutation in
blood (plasma or serum) cfDNA compared with paired tumour
tissue samples have ranged from 31% to 97% (Kimura et al, 2006,
2007; Moran et al, 2007; Bai et al, 2009; He et al, 2009; Kuang et al,
2009; Yung et al, 2009; Brevet et al, 2011; Goto et al, 2012; Liu et al,
2013; Zhao et al, 2013; Douillard et al, 2014b; Mok et al, 2015).
This wide variation could be due to multiple factors, including
differences in sample media (e.g., plasma vs serum), differences
in DNA extraction and mutation detection methodologies
(e.g., ARMS, digital PCR, or direct sequencing, among others),
disease stage of patients (e.g., high cfDNA levels have been
associated with more advanced disease; Lee et al, 2011), and the
inclusion of patients with wild-type EGFR. Indeed, it is easier to
establish the absence of an EGFR mutation in the blood than
confirm its presence, suggesting that the inclusion of patients with
wild-type EGFR may result in higher overall concordance rates
with paired tissue samples.
In LL3 and LL6, EGFR mutation-positive patients who were
cfDNAþ tended to have more advanced disease characteristics
compared with cfDNA patients, including higher ECOG
performance scores, greater tumour burden, a higher number of
metastatic sites, metastases to the bone and liver, and higher
laboratory values (e.g., ALP and LDH), which are associated with
metastatic spread to the bone/liver. This association may be a result
of increased escape of tumour cells and DNA into the blood in
patients with greater tumour burden and more metastatic sites.
Furthermore, the more advanced baseline disease characteristics of
EGFR cfDNAþ patients are likely to contribute to the poorer
prognosis of these patients, irrespective of treatment with afatinib
or chemotherapy. The correlation between the presence of mutant
EGFR in the blood and the increased number of metastatic sites has
been reported in a previous analysis (Lee et al, 2011). The higher
proportion of females among cfDNAþ patients observed in LL6 is
also consistent with some previous reports (Kimura et al, 2007;
Jiang et al, 2011). Although some studies have demonstrated a
correlation between cfDNAþ status and tumour histology, poor
differentiation status, and non-smoking status (Kimura et al, 2007;
Bai et al, 2009; Jiang et al, 2011; Zhao et al, 2013), such correlations
were not observed in this report.
The therapeutic sensitivity of EGFR mutation-positive NSCLC
to EGFR TKIs is well established (Yap and Popat, 2014). In this
context, previous studies have demonstrated improved clinical
outcomes in gefitinib-treated NSCLC patients with detectable
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EGFR mutations in serum (Kimura et al, 2006, 2007) and plasma
(Bai et al, 2009) vs patients with NSCLC harbouring wild-type
EGFR. The current study examined clinical outcomes in EGFR
mutation-positive patients diagnosed by tumour biopsy according
to their EGFR mutation status by cfDNA. In this analysis, clinical
benefit was observed with afatinib- vs platinum-based chemother-
apy whether or not the mutation could be found in the blood.
Interestingly, cfDNAþ patients displayed less favourable PFS and
OS, irrespective of treatment, compared with cfDNA patients,
despite similar ORRs in cfDNAþ and cfDNA patients. Similar
findings were observed in a recent study by Li et al (2014), in
which shorter PFS with EGFR TKI treatment was reported in
cfDNAþ vs cfDNA NSCLC patients with EGFR mutation-
positive tumours by biopsy. Subgroup analyses in the Phase III
EURTAC trial in EGFR mutation-positive patients also demon-
strated shorter PFS with erlotinib in cfDNAþ vs cfDNA
patients (Rosell et al, 2012). More recent analyses from the
EURTAC trial demonstrated that, in patients with L858R
mutations in the tumour, median OS was shorter for cfDNAþ
patients compared with those who were cfDNA (Karachaliou
et al, 2015); these findings are consistent with results from our
analysis. In contrast to our results, patients with tumour Del19
mutations who were also cfDNAþ had longer median OS than
patients who were cfDNA , and analysis of baseline disease
characteristics did not show any significant differences between
cfDNAþ and cfDNA patients (Karachaliou et al, 2015). In
recent analyses of the Phase III FASTACT-2 study, improved PFS
with erlotinib over placebo was noted in patients who were
cfDNAþ vs cfDNA for EGFR mutations at baseline. However,
for the baseline cfDNAþ subgroup, both PFS and OS were
significantly worse for those who were cfDNAþ at cycle 3 of
treatment compared with those who were cfDNA at cycle 3
(Mok et al, 2015). In the Phase III First-SIGNAL study, high EGFR
mutation positivity in plasma was associated with significantly
shorter survival in gefitinib-treated patients with lung adenocarci-
noma vs low EGFR mutation positivity (P¼ 0.03) (Lee et al, 2011).
Of note, high blood EGFR mutation positivity in the First-SIGNAL
study was also associated with more aggressive baseline tumour
characteristics (e.g., greater number of metastatic sites); Mok et al
(2015) also hypothesised that the changes in outcomes with
erlotinib may have been linked to increases in tumour burden
or metastases.
To our knowledge, the current analysis of the LL3 and LL6 trials
provides the largest cohort of data to date assessing both the
feasibility of detecting EGFR mutation in the blood and the
correlation of clinical characteristics and outcomes with cfDNAþ
status. In this context, there are some limitations of the analyses
that should be considered when interpreting the findings. First,
blood samples were not collected from all screened patients in
these studies, and the proportions of missing samples, while
generally low, were different between LL3 and LL6, which may be a
confounding factor in these analyses. Second, quantitative
measurement of the extracted DNA was not performed; thus we
were unable to determine whether there was a relationship between
DNA quantity and test positivity. In addition, because all patients
included in LL3 and LL6 had tumour tissue that was positive for
one or more EGFR mutation, we were unable to formally
determine the sensitivity and specificity of the methods to detect
these mutations, as compared with wild-type EGFR, in serum or
plasma. Further, the different sample media used in each study
(plasma vs serum) prevented combining the study data. Although
combination of the LL3 and LL6 data would have potentially
improved the overall statistical power of the outcomes analyses, the
separate analysis of plasma and serum did provide a preliminary
assessment of which media may be better for the detection of EGFR
mutations. As described in the Methods section, all analyses were
post hoc and therefore considered exploratory. No adjustment for
multiplicity was made to the P values presented, resulting in an
increased chance of false-positive results; however, the results were
generally consistent and of sufficient magnitude to suggest a true
effect rather than a chance finding. Finally, serial postbaseline
blood sampling was not conducted in LL3 and LL6; thus potential
changes in blood mutation status during treatment and at the time
of progression could not be assessed.
In summary, our findings suggest that detection of EGFR
mutation in cfDNA from plasma appears to be a promising and
minimally invasive alternative to tumour biopsy for patients
without available tissue samples. Patients with EGFR mutations
detected in the blood (irrespective of mutation type) displayed
more advanced disease characteristics and had worse prognosis
compared with blood EGFR mutation-negative patients. Impor-
tantly, clinical benefit with afatinib over platinum-based che-
motherapy was consistently observed in both cfDNAþ and
cfDNA populations. Improvements in the methodology of
cfDNA testing for EGFR mutations are needed to increase
sensitivity and to enable this to be offered to all patients considered
for EGFR-targeted therapy, with the goal of reducing the overall
burden of performing invasive biopsy procedures. Future pro-
spective studies in patients with paired tumour tissue and blood
samples will be important to further develop the utility of this
methodology with regard to patient prognosis and predicting
clinical outcomes.
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